Musab S Hommos1, An S De Vriese2, Mariam P Alexander3, Sanjeev Sethi3, Lisa Vaughan4, Ladan Zand1, Kharmen Bharucha1, Nicola Lepori1, Andrew D Rule1, Fernando C Fervenza5. 1. Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN. 2. Division of Nephrology, Sint-Jan Brugge-Oostende AV, Brugge, Belgium. 3. Department of Anatomic Pathology, Mayo Clinic, Rochester, MN. 4. Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN. 5. Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN. Electronic address: Fervenza.Fernando@mayo.edu.
Abstract
OBJECTIVES: To describe the change in the incidence rates of primary and secondary focal segmental glomerulosclerosis (FSGS) from 1994 through 2013 in Olmsted County, Minnesota, and to identify the clinical and biopsy characteristics that distinguish primary from secondary FSGS. PATIENTS AND METHODS: Olmsted County adult residents with native kidney biopsy from January 1, 1994, through December 31, 2013, and FSGS as the only glomerulopathy were identified. The clinical and pathologic characterstics of primary and secondary FSGS were described and compared, and incidence rates were calculated. RESULTS: Of 370 adults biopsied, 281 had glomerular diseases, of which 46 (16%) had FSGS. From 1994-2003 to 2004-2013, there were significant increases in kidney biopsy rates (14.7 [95% CI, 12.1-17.3] vs 22.9 [95% CI, 20.0-25.7] per 100,000 person-years, 17% increase per 5 years; P<.001) and total FSGS rates (1.4 [95% CI, 0.6-2.2] vs 3.2 [95% CI, 2.1-4.3] per 100,000 person-years, 41% increase per 5 years; P=.02). Compared with patients with limited foot process effacement (<80%), patients with diffuse effacement (≥80%) without an identifiable cause had lower serum albumin levels (P<.001), had higher proteinuria (P<.001), and were more likely to have nephrotic syndrome (100% vs 4%; P<.001). Patients with diffuse effacement without an identifiable cause were classified as primary FSGS, which accounted for 3 of 12 patients (25%) during 1994-2003 and 9 of 34 (26%) during 2004-2013. CONCLUSION: Although the incidence of FSGS has increased, the proportions of primary and secondary FSGS have remained stable.
OBJECTIVES: To describe the change in the incidence rates of primary and secondary focal segmental glomerulosclerosis (FSGS) from 1994 through 2013 in Olmsted County, Minnesota, and to identify the clinical and biopsy characteristics that distinguish primary from secondary FSGS. PATIENTS AND METHODS: Olmsted County adult residents with native kidney biopsy from January 1, 1994, through December 31, 2013, and FSGS as the only glomerulopathy were identified. The clinical and pathologic characterstics of primary and secondary FSGS were described and compared, and incidence rates were calculated. RESULTS: Of 370 adults biopsied, 281 had glomerular diseases, of which 46 (16%) had FSGS. From 1994-2003 to 2004-2013, there were significant increases in kidney biopsy rates (14.7 [95% CI, 12.1-17.3] vs 22.9 [95% CI, 20.0-25.7] per 100,000 person-years, 17% increase per 5 years; P<.001) and total FSGS rates (1.4 [95% CI, 0.6-2.2] vs 3.2 [95% CI, 2.1-4.3] per 100,000 person-years, 41% increase per 5 years; P=.02). Compared with patients with limited foot process effacement (<80%), patients with diffuse effacement (≥80%) without an identifiable cause had lower serum albumin levels (P<.001), had higher proteinuria (P<.001), and were more likely to have nephrotic syndrome (100% vs 4%; P<.001). Patients with diffuse effacement without an identifiable cause were classified as primary FSGS, which accounted for 3 of 12 patients (25%) during 1994-2003 and 9 of 34 (26%) during 2004-2013. CONCLUSION: Although the incidence of FSGS has increased, the proportions of primary and secondary FSGS have remained stable.
Authors: José G van den Berg; Marius A van den Bergh Weerman; Karel J M Assmann; Jan J Weening; Sandrine Florquin Journal: Kidney Int Date: 2004-11 Impact factor: 10.612
Authors: An S De Vriese; Sanjeev Sethi; Karl A Nath; Richard J Glassock; Fernando C Fervenza Journal: J Am Soc Nephrol Date: 2018-01-10 Impact factor: 10.121
Authors: Thabata Caroline de Oliveira Santos; Gabriel Pereira; Anna Gabrielle Gomes Coutinho; Halison Pereira Dos Santos Silva; Marcelo M S Lima; Fernando Augusto Lavezzo Dias; Danilo Cândido de Almeida; Débora Tavares Resende E Silva; Ricardo Fernandez Perez; Rafael Luiz Pereira Journal: Mol Cell Biochem Date: 2022-10-06 Impact factor: 3.842
Authors: Virginie Royal; Jarcy Zee; Qian Liu; Carmen Avila-Casado; Abigail R Smith; Gang Liu; Laura H Mariani; Stephen Hewitt; Lawrence B Holzman; Brenda W Gillespie; Jeffrey B Hodgin; Laura Barisoni Journal: J Am Soc Nephrol Date: 2020-02-21 Impact factor: 10.121
Authors: Keng Thye Woo; Choong Meng Chan; Cynthia Lim; Jason Choo; Yok Mooi Chin; Esther Wei Ling Teng; Irene Mok; Jia Liang Kwek; Alwin H L Loh; Hui Lin Choong; Han Kim Tan; Grace S L Lee; Evan Lee; Kok Seng Wong; Puay Hoon Tan; Marjorie Foo Journal: Kidney Dis (Basel) Date: 2019-06-11
Authors: Jennifer A Schaub; Christopher L O'Connor; Jian Shi; Roger C Wiggins; Kerby Shedden; Jeffrey B Hodgin; Markus Bitzer Journal: J Clin Pathol Date: 2021-01-11 Impact factor: 4.463